Annual report pursuant to Section 13 and 15(d)

License Agreements (Details)

v3.24.1
License Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2015
May 11, 2015
May 31, 2016
Mar. 31, 2015
Dec. 31, 2023
Dec. 31, 2022
Feb. 28, 2023
Dec. 31, 2021
Jan. 31, 2019
License Agreements                  
Sale price per share             $ 5.25    
Research and development                  
License Agreements                  
Value of common stock shares issued         $ 3,400,000 $ 1,900,000      
NeuPharma, Inc.                  
License Agreements                  
Payment of upfront licensing fees       $ 1,000,000.0          
NeuPharma, Inc. | Additional sales milestone                  
License Agreements                  
Maximum potential milestone payments       40,000,000.0          
NeuPharma, Inc. | Clinical and development milestone                  
License Agreements                  
Maximum potential milestone payments       39,000,000.0          
NeuPharma, Inc. | Regulatory approvals to commercialize the products                  
License Agreements                  
Maximum potential milestone payments       22,500,000          
Dana-Farber Cancer Institute                  
License Agreements                  
Payment of upfront licensing fees       $ 1,000,000.0          
Number of shares of common stock granted 13,683 50,000              
Value of common stock shares issued $ 600,000 $ 32,500              
Sale price per share   $ 0.65              
Ownership percentage       5.00%          
Cash in exchange for common shares       $ 10,000,000          
Amount of milestone expensed         5,000,000.0        
Maintenance fee       50,000          
Dana-Farber Cancer Institute | First commercial sale milestone                  
License Agreements                  
Maximum potential milestone payments       21,500,000          
Dana-Farber Cancer Institute | Additional sales milestone                  
License Agreements                  
Maximum potential milestone payments       $ 60,000,000.0          
Adimab, LLC | PD-L1 | Research and development                  
License Agreements                  
Non-Refundable milestone payment               $ 2,200,000  
Adimab, LLC | Regulatory approvals to commercialize the products                  
License Agreements                  
Maximum potential milestone payments                 $ 2,500,000
Jubilant Biosys Limited                  
License Agreements                  
Payment of upfront licensing fees     $ 2,000,000.0            
Jubilant Biosys Limited | Clinical and development milestone                  
License Agreements                  
Maximum potential milestone payments     88,400,000            
Jubilant Biosys Limited | Regulatory approvals to commercialize the products                  
License Agreements                  
Maximum potential milestone payments     59,500,000            
Jubilant Biosys Limited | Sale Millstone                  
License Agreements                  
Maximum potential milestone payments     $ 89,300,000            
Collaboration Agreement With TGTX                  
License Agreements                  
Revenue recognition milestone revenue recognized         $ 58,000 $ 121,000      
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]         Revenues Revenues      
Sublicense Agreement with TGTX                  
License Agreements                  
Revenue recognition milestone revenue recognized         $ 46,000 $ 70,000